Gaucher Disease News and Research

RSS
Genzyme third quarter revenue increases to $1.0 billion

Genzyme third quarter revenue increases to $1.0 billion

New disease pathways involving more than one cell type lead to Type 1 Gaucher disease: Study

New disease pathways involving more than one cell type lead to Type 1 Gaucher disease: Study

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme second-quarter revenue decreases to $1.08 billion

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

Genzyme to initiate $2 billion stock buyback

Genzyme to initiate $2 billion stock buyback

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics' personal Genetic Health Report now available

Shire receives marketing approval from FDA for VPRIV

Shire receives marketing approval from FDA for VPRIV

Gaucher disease: FDA approves VPRIV

Gaucher disease: FDA approves VPRIV

Shire reports total revenues of $3,008 million for 2009

Shire reports total revenues of $3,008 million for 2009